Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Area of Science:

• Oncology
• Immunotherapy
• Biomarker Research

Background:

• Nivolumab plus ipilimumab demonstrated promising efficacy in prior non-small-cell lung cancer (NSCLC) trials.
• Tumor mutational burden (TMB) emerged as a potential predictive biomarker for treatment response.
• This phase 3 trial segment evaluated the efficacy of nivolumab plus ipilimumab versus chemotherapy in NSCLC patients with high TMB.

Purpose of the Study:

• To assess progression-free survival (PFS) in previously untreated stage IV or recurrent NSCLC patients with high TMB.
• To compare the efficacy of nivolumab plus ipilimumab against standard chemotherapy.
• To evaluate the role of TMB as a biomarker for selecting patients for this immunotherapy combination.

Main Methods:

• Open-label, multipart, phase 3 trial enrollment of patients with stage IV or recurrent NSCLC.
• Random assignment to nivolumab plus ipilimumab, nivolumab monotherapy, or chemotherapy based on PD-L1 expression levels.
• Tumor mutational burden (TMB) assessed using the FoundationOne CDx assay (high TMB defined as ≥10 mutations per megabase).

Main Results:

• Significantly longer progression-free survival (PFS) observed with nivolumab plus ipilimumab compared to chemotherapy in high TMB NSCLC patients.
• 1-year PFS rates were 42.6% for nivolumab plus ipilimumab vs. 13.2% for chemotherapy; median PFS was 7.2 months vs. 5.5 months.
• Objective response rate was higher with nivolumab plus ipilimumab (45.3%) than chemotherapy (26.9%), with manageable grade 3/4 adverse events.

Conclusions:

• First-line nivolumab plus ipilimumab significantly improves PFS in NSCLC patients with high TMB, irrespective of PD-L1 status.
• The study validates the efficacy of nivolumab plus ipilimumab in NSCLC.
• Tumor mutational burden is confirmed as a valuable biomarker for patient selection in this treatment setting.